Corneal Toxicity in Patients Receiving Antibody–Drug Conjugates for the Treatment of Cancer

Learn from experts about the monitoring and management recommendations for corneal events associated with antibody&ndash drug conjugates used to treat patients with cancer. Review expert insights in a clinical commentary along with downloadable slides and on-demand webcast adapted from a live CCO webinar.

Share

Program Content

No activities added yet

No activities added yet

No activities added yet

No activities added yet

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

GlaxoSmithKline